$98.82
+0.40 (+0.41%)
Open$99.79
Previous Close$98.42
Day High$100.34
Day Low$97.14
52W High$99.80
52W Low$12.84
Volume—
Avg Volume786.6K
Market Cap5.99B
P/E Ratio—
EPS$-2.39
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-79.1% upside
Current
$98.82
$98.82
Target
$20.70
$20.70
$16.39
$20.70 avg
$27.30
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 372.50M | 351.85M | 301.99M |
| Net Income | -104,674,461 | -84,234,881 | -79,583,487 |
| Profit Margin | -28.1% | -23.9% | -26.4% |
| EBITDA | -120,858,001 | -107,157,018 | -93,330,324 |
| Free Cash Flow | -75,919,374 | -55,757,162 | -73,499,960 |
| Rev Growth | -6.8% | +18.4% | +6.2% |
| Debt/Equity | 0.83 | 0.74 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |